Clinical trials
Chronic Graft Versus Host Disease clinical trials
Below are recruiting chronic graft versus host disease clinical trials, each written for real people, not researchers. We’re tracking 71 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT02918188RecruitingPhase 2
Hydrogen therapy for steroid-resistant graft-versus-host disease
This Phase 2 study tests whether hydrogen therapy can improve symptoms in people with chronic graft-versus-host disease (cGVHD) who cannot tolerate steroid treatment. If steroids aren’t working or can’t be used, this trial may offer an alternative approach to help control the illness.
Beijing, Beijing MunicipalityAges Up to 65 years - NCT06423131Recruiting
Comparing two types of stem cell transplants for children
This study compares a newer type of stem cell transplant (using special cells) to the standard method for children who need a half-matched donor. It aims to see if the new approach is safer and works as well.
Shanghai, Shanghai MunicipalityAges 2 months–18 years - NCT07803978Enrolling by invitationEarly Phase 1
Study of Amimaitosai plus steroids for gut graft-versus-host disease
This study tests whether adding an investigational drug called Amimaitosai to standard steroids helps control gut symptoms caused by graft-versus-host disease after a stem cell transplant. It may offer a new option to reduce these symptoms and improve recovery.
Beijing, Beijing MunicipalityAges 14 years+ - NCT07794800Recruiting
Observing eye complications after stem cell transplant
This study observes patients who have had a stem cell transplant to understand and monitor chronic graft-versus-host disease affecting the eyes. It aims to learn more about this condition to improve future care.
Shanghai, Shanghai MunicipalityAges 14 years+ - NCT07776210RecruitingPhase 3
Eye drops for chronic dry eye after stem cell transplant
This trial tests an eye drop solution for people with chronic dry eye caused by graft-versus-host disease after a stem cell transplant. It aims to see if the drops can reduce eye discomfort and improve the eye surface.
Beverly Hills, CaliforniaAges 18 years+ - NCT07606703RecruitingPhase 2
Madecassoside for Hardened Skin After Bone Marrow Transplant
This trial tests whether a plant-derived medicine called madecassoside can help treat sclerotic chronic graft-versus-host disease (a hardening and tightening of the skin that sometimes happens after bone marrow transplant). You would take tablets and be monitored to see if your skin condition improves.
Wuhan, HubeiAges 14–65 - NCT07594587Recruiting
Ruxolitinib for Graft-Versus-Host Disease
This study looks at how well a medicine called ruxolitinib works for patients with graft-versus-host disease (GVHD)—a condition where donor cells attack your body after a bone marrow or stem cell transplant. The trial aims to understand if ruxolitinib can help control this side effect.
TokyoAges birth+ - NCT07570745RecruitingPhase 2
Stem cell transplant with new drugs to prevent GVHD
This trial tests a combination of medications given before and after a stem cell transplant from a family member to prevent graft-versus-host disease (GVHD)—a condition where the new cells attack your body. The study includes a newer drug called ivarmacitinib that may help reduce this serious side effect.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07566377RecruitingPhase 2
Cord Blood Transplant for Children and Young Adults With Blood Cancer
This study tests whether using cord blood stem cells (collected from umbilical cords after birth) can help treat high-risk blood cancers in children and young adults when a matched donor is not quickly available. Cord blood transplants may help prevent cancer from coming back.
New York, New YorkAges Up to 26 years - NCT07535008Recruiting
Dental Cleaning to Prevent Graft-Versus-Host Disease
This study tests whether professional dental cleaning after a stem cell transplant can help prevent chronic graft-versus-host disease (GVHD), a condition where transplanted immune cells attack your body. You'll receive dental cleanings and be followed for one year to see if this simple preventive step reduces GVHD complications.
Seattle, WashingtonAges 18 years+ - NCT06756061RecruitingPhase 2
Ruxolitinib and steroids for chronic graft-versus-host disease
This trial tests whether adding ruxolitinib to standard steroid treatment works better than steroids alone for people with moderate to severe chronic graft-versus-host disease (cGVHD). cGVHD is a condition where donor immune cells attack the body after a stem cell transplant.
Seoul, Banpo-daero/Seocho-guAges 19 years+ - NCT07325253RecruitingPhase 2
PET scan to see graft-versus-host disease activity
This study tests a new PET imaging agent to see if it can show areas of graft-versus-host disease (GVHD) in the body. If it works, it might help doctors better understand and manage GVHD after a stem cell transplant.
Houston, TexasAges 18 years+ - NCT07314892Recruiting
Psychiatric health and symptom severity in GvHD patients
This study looks at how graft-versus-host disease (a complication after a bone marrow transplant) affects mental health and symptom severity. It aims to understand the connection so that doctors can better support patients.
Gdansk, Pomeranian VoivodeshipAges 18–75 - NCT07297303Recruiting
Lung health study after stem cell transplant
This study follows lung health after a stem cell transplant from a donor, to understand and manage chronic graft-versus-host disease (a condition where donor cells attack the body). It may help people who are about to have their first donor transplant.
TaipeiAges 18 years+ - NCT07285889RecruitingPhase 1/Phase 2
Jaktinib as first treatment for acute graft-versus-host disease
This trial tests a new pill called jaktinib for people who develop moderate to severe acute graft-versus-host disease (aGVHD) after a stem cell transplant. The goal is to see if adding jaktinib to standard steroid therapy can better control the disease.
Hangzhou, ZhejiangAges 18 years+ - NCT07253259RecruitingEarly Phase 1
Cell therapy for hard-to-treat chronic graft-versus-host disease
This study tests a new cell therapy called GT729 for people with chronic graft-versus-host disease (cGVHD) that hasn't improved with at least two previous treatments. The therapy is given as an injection and aims to help control the immune system reaction that causes cGVHD.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT07246031RecruitingPhase 2
BPC2001 to Prevent Graft-Versus-Host Disease After Stem Cell Transplant
This trial tests a new drug, BPC2001, to see if it can prevent graft-versus-host disease (a common complication where donor cells attack the patient's body) in people receiving a half-matched stem cell transplant from a family donor. It may be an option for adults with certain blood cancers who are planning their first transplant.
Beijing, Beijing MunicipalityAges 18–65 - NCT07249346RecruitingPhase 2
Preventing GVHD after stem cell transplant with three drugs
This trial tests a three-drug combination (cyclophosphamide, tacrolimus, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for people with certain blood cancers who have a matched donor and can tolerate high-dose chemotherapy.
Birmingham, AlabamaAges 18 years+ - NCT07235501Recruiting
Understanding immune cells after stem cell transplant
This study looks at immune cells in your blood and in tissues affected by chronic graft-versus-host disease (a condition where donor cells attack your body) after a stem cell transplant. By analyzing samples, researchers hope to better understand this condition and improve future treatments.
Duarte, CaliforniaAges 7 years+ - NCT06904599RecruitingPhase 2
Testing hCG for acute GVHD after a stem cell transplant
This study tests if a hormone called hCG can help treat moderate-to-severe graft-versus-host disease (GVHD) after a stem cell transplant. It is for adults who have recently developed GVHD and need steroids, but have not been on high-dose steroids for long.
Monterrey, Nuevo LeónAges 18 years+ - NCT07185633RecruitingPhase 2
Study of Gecacitinib and Steroids for Acute Graft-Versus-Host Disease
This study tests a new pill (gecacitinib) combined with steroids as the first treatment for moderate to severe acute graft-versus-host disease after a stem cell transplant. The goal is to see if this combination works better than steroids alone.
Suzhou, JiangsuAges 18 years+ - NCT07166848Enrolling by invitation
Electrical stimulation study for dry eye from graft vs. host disease
This trial tests if gentle electrical stimulation around the eye can help relieve dry eye symptoms caused by chronic graft versus host disease (a complication after a stem cell or bone marrow transplant). It is for people with moderate to severe dry eye who have not had recent eye surgeries or certain other eye problems.
Boston, MassachusettsAges 18–75 - NCT07138196RecruitingPhase 1
Adrixetinib for hard-to-treat chronic GvHD
This trial tests an experimental drug called adrixetinib (Q702) for people with active chronic graft-versus-host disease that has not responded well to standard treatments. It aims to see if the drug can help control your symptoms when other options have stopped working.
BarcelonaAges 18 years+ - NCT07127926RecruitingPhase 1
Belumosudil pill vs crushed pill study for chronic GVHD
This trial tests whether crushing belumosudil tablets changes how the drug works in people with chronic graft-versus-host-disease (GVHD), a complication after a stem cell transplant. It helps doctors know if taking crushed pills is as effective as whole tablets.
Houston, TexasAges 18 years+
Hear when a new Chronic Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Chronic Graft Versus Host Disease trials by city
Studies with a site in or near these metro areas.
Chronic Graft Versus Host Disease trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for chronic graft versus host disease?
- Yes. Clin2 currently lists 71 recruiting chronic graft versus host disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic graft versus host disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic graft versus host disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.